29 July 2019

De Brauw advised Pfizer on the spin-off of Pfizer’s Upjohn business and its merger with Mylan

De Brauw is pleased to have advised Pfizer Inc. alongside Wachtell, Lipton, Rosen & Katz on the spin-off of Pfizer’s Upjohn business and its merger with Mylan, creating a new global pharmaceutical company.

De Brauw lead partner Paul Cronheim reflects: “By successfully advising Pfizer and Wachtell on this landmark transaction, we have once again shown that De Brauw is the go-to Dutch law firm for large and complex international M&A matters. Our extensive experience with these types of cross-border transactions and our integrated teams of specialists combining corporate, M&A, finance and tax capabilities enabled us to add value on key topics such as the transaction structure, deal certainty and tax implications. We are happy to add this transaction to our international track record and look forward to working with Pfizer and Wachtell to complete this transaction.”

Team effort by: Paul Cronheim, Casper Nagtegaal, Nathalie van Wiggen, Harald van Wijlen, Maarten van der Weijden, Wiebe Dijkstra and Joppe de Bruijn.

We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.
Accept cookiesChange cookiesClick here for more information about our cookies.